NDA 219627 · Bayer Healthcare
Ambelvist
Gadoquatrane · Intravenous
NovelOrphanCDER novel approval, Jun 12, 2026: To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jun 12, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. AMBELVIST is not approved for intrathecal use [see Warnings and Precautions (5.1) ]. Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of AMBELVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m 2 ), or Acute kidney injury....
What it is approved for
From the label in effect Jun 12, 2025.
AMBELVIST is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) AMBELVIST is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) ( 1 )
Mechanism: Gadoquatrane is a paramagnetic tetrameric macrocyclic non-ionic complex of gadolinium that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in the signal intensity (brightness) of tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2026 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelMedication GuideReview
6 products under this application
- AMBELVIST · GADOQUATRANE 7.737GM/30ML (257.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMBELVIST · GADOQUATRANE 2.579GM/10ML (257.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMBELVIST · GADOQUATRANE 0.5158GM/2ML (257.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMBELVIST · GADOQUATRANE 16.7635GM/65ML (257.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMBELVIST · GADOQUATRANE 3.8685GM/15ML (257.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- AMBELVIST · GADOQUATRANE 1.93425GM/7.5ML (257.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadoquatrane" as an intervention, any sponsor and status, largest first.
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915728 · 410 participants · Start Jul 24, 2023 · Primary completion May 31, 2024
Drug: Gadoquatrane (BAY1747846); Gadobutrol and 2 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Non-central Nervous System Pathology
Sites: Birmingham, Alabama; Indian Wells, California; Orange, California · 85 sites in all
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related ProblemsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915702 · 321 participants · Start Jul 24, 2023 · Primary completion May 30, 2024
Drug: Gadoquatrane (BAY1747846); Gadobutrol and 2 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Central Nervous System Pathology
Sites: Indian Wells, California; Orange, California; Miami, Florida · 78 sites in all
- A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915026 · 105 participants · Start Aug 16, 2023 · Primary completion Sep 18, 2024
Drug: Gadoquatrane (BAY1747846) · For: Contrast Enhancement in Magnetic Resonance Imaging; Children
Sites: Indian Wells, California; Kansas City, Missouri; Charleston, South Carolina · 34 sites in all
BayerBayer (BAYRY)
NCT04307186 · 57 participants · Start Nov 18, 2020 · Primary completion Sep 5, 2022
Drug: Gadoquatrane (BAY1747846); Gadobutrol (Gadovist/Gadavist) · For: Central Nervous System Pathology
Sites: Chicago, Illinois; Iowa City, Iowa; Hershey, Pennsylvania · 17 sites in all
BayerBayer (BAYRY)
NCT06135181 · 24 participants · Start Aug 26, 2020 · Primary completion Feb 2, 2021
Drug: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg; Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg and 1 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Healthy Volunteers
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics, Safety, and Dialyzability of Gadoquatrane in Patients With Impaired Renal Function: A Comprehensive Investigation Using Clinical Trial Data, Modeling and Simulation, and In Vitro Data.
Fadini T, Sutter G, Klein S, et al. · Invest Radiol 2025 · Clinical Trial
- Relationship of Dose and Signal Enhancement Properties of Gadoquatrane, a New Tetrameric, Macrocyclic Gadolinium-Based Contrast Agent, Compared With Gadobutrol: A Randomized Crossover Study in Healthy Adults.
Hofmann BM, Riecke K, Klein S, et al. · Invest Radiol 2024 · Randomized Controlled Trial, Comparative Study
- Pharmacokinetics, safety, and tolerability of the novel tetrameric gadolinium-based MRI contrast agent gadoquatrane in healthy Chinese and Japanese men: Two randomized dose-escalation studies including concentration-QTc modeling.
He X, Matsuki S, Li K, et al. · Eur J Pharm Sci 2024 · Randomized Controlled Trial
- Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults.
Hofmann BM, Riecke K, Klein S, et al. · Invest Radiol 2024 · Randomized Controlled Trial
- Rationales for Non-standard GBCA Dosing-Low?-High?-When? and Why?: A Literature-based Study.
Endrikat J, Siddiqui I, Khater H, et al. · Invest Radiol 2026 · Systematic Review
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.